A postmarketing study of relative abuse liability of hypnotic sedative drugs

Jerome H. Jaffe, Roger Bloor, Ilana Crome, Malcolm Carr, Farrukh Alam, Arnol Simmons, Roger Meyer

Research output: Contribution to journalReview article

49 Citations (Scopus)

Abstract

Aims: To demonstrate the utility of postmarketing studies using in-treatment drug and alcohol abusers as informants for assessing the relative abuse liability of sedative-hypnotic drugs. Design: A survey was conducted that ascertained exposure to a variety of drugs with hypnotic/sedative properties and elicited subjective evaluations indicative of abuse liability. Methods: Complete data were obtained from 297 admissions (78% male) to three addiction treatment sites in the United Kingdom. Subjects were asked 15 questions about 12 different drugs, including five benzodiazepines, three anti-depressants, two non-benzodiazepine hypnotics and two antihistamines (plus one fictitious drug). Three of the benzodiazepines (diazepam, nitrazipam, temazepam) emerged as having substantially more abuse liability than any of the other drugs tested, as revealed by higher scores on abuse liability items (purchased on street, taken to get high, like drug, potential for addiction to drug). The antihistamines (chlorpheniramine, diphenhydramine) had lowest abuse liability profiles, while the antidepressants (amitriptyline, fluoxetine, trazadone) and non-benzodiazepine hypnotics (zolpidem, zopiclone) had similar profiles. Conclusion: This pilot study suggests that postmarketing information on hypnotic drug use obtained from drug addicts entering treatment produces data consistent with other measures of abuse liability. The data suggest that the risk of misuse of newer non-benzodiazepine hypnotics may be less than that of benzodiazepine drugs, and similar to that of sedating antidepressants. The new methodology may serve to clarify or validate premarketing abuse liability data, and may help to inform the regulatory process and physician practice.

Original languageEnglish (US)
Pages (from-to)165-173
Number of pages9
JournalAddiction
Volume99
Issue number2
DOIs
StatePublished - Feb 1 2004

Fingerprint

Hypnotics and Sedatives
Pharmaceutical Preparations
Benzodiazepines
zopiclone
Histamine Antagonists
Drug Users
Antidepressive Agents
Chlorpheniramine
Diphenhydramine
Amitriptyline
Temazepam
Fluoxetine
Diazepam
Substance-Related Disorders
Therapeutics
Alcohols
Physicians

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Cite this

Jaffe, J. H., Bloor, R., Crome, I., Carr, M., Alam, F., Simmons, A., & Meyer, R. (2004). A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction, 99(2), 165-173. https://doi.org/10.1111/j.1360-0443.2003.00631.x
Jaffe, Jerome H. ; Bloor, Roger ; Crome, Ilana ; Carr, Malcolm ; Alam, Farrukh ; Simmons, Arnol ; Meyer, Roger. / A postmarketing study of relative abuse liability of hypnotic sedative drugs. In: Addiction. 2004 ; Vol. 99, No. 2. pp. 165-173.
@article{e7b0d64339c24c078250e7fb470e3303,
title = "A postmarketing study of relative abuse liability of hypnotic sedative drugs",
abstract = "Aims: To demonstrate the utility of postmarketing studies using in-treatment drug and alcohol abusers as informants for assessing the relative abuse liability of sedative-hypnotic drugs. Design: A survey was conducted that ascertained exposure to a variety of drugs with hypnotic/sedative properties and elicited subjective evaluations indicative of abuse liability. Methods: Complete data were obtained from 297 admissions (78{\%} male) to three addiction treatment sites in the United Kingdom. Subjects were asked 15 questions about 12 different drugs, including five benzodiazepines, three anti-depressants, two non-benzodiazepine hypnotics and two antihistamines (plus one fictitious drug). Three of the benzodiazepines (diazepam, nitrazipam, temazepam) emerged as having substantially more abuse liability than any of the other drugs tested, as revealed by higher scores on abuse liability items (purchased on street, taken to get high, like drug, potential for addiction to drug). The antihistamines (chlorpheniramine, diphenhydramine) had lowest abuse liability profiles, while the antidepressants (amitriptyline, fluoxetine, trazadone) and non-benzodiazepine hypnotics (zolpidem, zopiclone) had similar profiles. Conclusion: This pilot study suggests that postmarketing information on hypnotic drug use obtained from drug addicts entering treatment produces data consistent with other measures of abuse liability. The data suggest that the risk of misuse of newer non-benzodiazepine hypnotics may be less than that of benzodiazepine drugs, and similar to that of sedating antidepressants. The new methodology may serve to clarify or validate premarketing abuse liability data, and may help to inform the regulatory process and physician practice.",
author = "Jaffe, {Jerome H.} and Roger Bloor and Ilana Crome and Malcolm Carr and Farrukh Alam and Arnol Simmons and Roger Meyer",
year = "2004",
month = "2",
day = "1",
doi = "10.1111/j.1360-0443.2003.00631.x",
language = "English (US)",
volume = "99",
pages = "165--173",
journal = "Addiction",
issn = "0965-2140",
publisher = "Wiley-Blackwell",
number = "2",

}

Jaffe, JH, Bloor, R, Crome, I, Carr, M, Alam, F, Simmons, A & Meyer, R 2004, 'A postmarketing study of relative abuse liability of hypnotic sedative drugs', Addiction, vol. 99, no. 2, pp. 165-173. https://doi.org/10.1111/j.1360-0443.2003.00631.x

A postmarketing study of relative abuse liability of hypnotic sedative drugs. / Jaffe, Jerome H.; Bloor, Roger; Crome, Ilana; Carr, Malcolm; Alam, Farrukh; Simmons, Arnol; Meyer, Roger.

In: Addiction, Vol. 99, No. 2, 01.02.2004, p. 165-173.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A postmarketing study of relative abuse liability of hypnotic sedative drugs

AU - Jaffe, Jerome H.

AU - Bloor, Roger

AU - Crome, Ilana

AU - Carr, Malcolm

AU - Alam, Farrukh

AU - Simmons, Arnol

AU - Meyer, Roger

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Aims: To demonstrate the utility of postmarketing studies using in-treatment drug and alcohol abusers as informants for assessing the relative abuse liability of sedative-hypnotic drugs. Design: A survey was conducted that ascertained exposure to a variety of drugs with hypnotic/sedative properties and elicited subjective evaluations indicative of abuse liability. Methods: Complete data were obtained from 297 admissions (78% male) to three addiction treatment sites in the United Kingdom. Subjects were asked 15 questions about 12 different drugs, including five benzodiazepines, three anti-depressants, two non-benzodiazepine hypnotics and two antihistamines (plus one fictitious drug). Three of the benzodiazepines (diazepam, nitrazipam, temazepam) emerged as having substantially more abuse liability than any of the other drugs tested, as revealed by higher scores on abuse liability items (purchased on street, taken to get high, like drug, potential for addiction to drug). The antihistamines (chlorpheniramine, diphenhydramine) had lowest abuse liability profiles, while the antidepressants (amitriptyline, fluoxetine, trazadone) and non-benzodiazepine hypnotics (zolpidem, zopiclone) had similar profiles. Conclusion: This pilot study suggests that postmarketing information on hypnotic drug use obtained from drug addicts entering treatment produces data consistent with other measures of abuse liability. The data suggest that the risk of misuse of newer non-benzodiazepine hypnotics may be less than that of benzodiazepine drugs, and similar to that of sedating antidepressants. The new methodology may serve to clarify or validate premarketing abuse liability data, and may help to inform the regulatory process and physician practice.

AB - Aims: To demonstrate the utility of postmarketing studies using in-treatment drug and alcohol abusers as informants for assessing the relative abuse liability of sedative-hypnotic drugs. Design: A survey was conducted that ascertained exposure to a variety of drugs with hypnotic/sedative properties and elicited subjective evaluations indicative of abuse liability. Methods: Complete data were obtained from 297 admissions (78% male) to three addiction treatment sites in the United Kingdom. Subjects were asked 15 questions about 12 different drugs, including five benzodiazepines, three anti-depressants, two non-benzodiazepine hypnotics and two antihistamines (plus one fictitious drug). Three of the benzodiazepines (diazepam, nitrazipam, temazepam) emerged as having substantially more abuse liability than any of the other drugs tested, as revealed by higher scores on abuse liability items (purchased on street, taken to get high, like drug, potential for addiction to drug). The antihistamines (chlorpheniramine, diphenhydramine) had lowest abuse liability profiles, while the antidepressants (amitriptyline, fluoxetine, trazadone) and non-benzodiazepine hypnotics (zolpidem, zopiclone) had similar profiles. Conclusion: This pilot study suggests that postmarketing information on hypnotic drug use obtained from drug addicts entering treatment produces data consistent with other measures of abuse liability. The data suggest that the risk of misuse of newer non-benzodiazepine hypnotics may be less than that of benzodiazepine drugs, and similar to that of sedating antidepressants. The new methodology may serve to clarify or validate premarketing abuse liability data, and may help to inform the regulatory process and physician practice.

UR - http://www.scopus.com/inward/record.url?scp=1342322732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342322732&partnerID=8YFLogxK

U2 - 10.1111/j.1360-0443.2003.00631.x

DO - 10.1111/j.1360-0443.2003.00631.x

M3 - Review article

C2 - 14756709

AN - SCOPUS:1342322732

VL - 99

SP - 165

EP - 173

JO - Addiction

JF - Addiction

SN - 0965-2140

IS - 2

ER -

Jaffe JH, Bloor R, Crome I, Carr M, Alam F, Simmons A et al. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction. 2004 Feb 1;99(2):165-173. https://doi.org/10.1111/j.1360-0443.2003.00631.x